UnknownPhase 3

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

United States343 participantsStarted 2016-07

Plain-language summary

The purpose of this study is to compare the efficacy and safety of eflornithine in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has recurred/progressed after radiation and temozolomide chemotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Gd-contrast lesion margins are not clearly defined,
✓. Gd-contrast lesions are only measurable in one dimension,
✓. Gd-contrast lesion has two perpendicular diameters less than 10 mm,
✓. Gd-contrast lesion has two perpendicular diameters greater than 10 mm but less than 20 mm and lesion does not demonstrate central necrosis,
✓. Recent histopathological confirmation of WHO grade 3 AA

What they're measuring

Overall survival

Timeframe: 4 years

Trial details

NCT IDNCT02796261

SponsorOrbus Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-06

View on ClinicalTrials.gov More Anaplastic Astrocytoma trials